New Delhi:Mankind Pharma Ltd on Thursday said it has entered into an exclusive in-licensing and marketing agreement with China's Chongqing Chenan Biopharmaceutical Co Ltd for commercialisation of two insulin analogues in India for diabetes care. The agreement covers commercialisation of insulin degludec and insulin degludec, as part of a combination, the company said in a statement. The addition of these products will further enhance Mankind Pharma's position in the injectable diabetes segment, contributing to a more comprehensive portfolio and reinforcing its commitment to addressing the evolving needs of patients, it added.